Annals of Oncology 13:1285-1289, 2002
© 2002 European Society for Medical Oncology
Original Paper |
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin’s lymphoma
1 Department of Medicine III, University Hospital, Frankfurt am Main; 2 Department of Medicine V, Städtische Kliniken Darmstadt, Germany
Received 4 October 2001; revised 24 January 2002; accepted 19 February 2002
Background:
Bendamustine, an alkylating agent with a nitrogen mustard group and a purine-like benzimidazol group, has been shown to be effective in several solid tumors and indolent non-Hodgkin’s lymphomas, but has not yet been studied for efficacy in aggressive lymphomas.
Patients and methods:
We conducted a phase II study in patients with relapsed or refractory high-grade non-Hodgkin’s lymphomas, using bendamustine at a dose of 120 mg/m2 on days 1 and 2, every 3 weeks for up to six cycles. Twenty-one patients were enrolled; 18 were evaluable for response and toxicity, 10 of whom were refractory to previous chemotherapy.
Results:
With three patients achieving a complete response (at 6, 
8 and 22 months) and five a partial response (three at 2 months, one at 3 months and one at 10 months), the total response rate of the evaluable patients was 44% (eight out of 18; 38% of all patients). Two complete and two partial responders were refractory to prior treatment. In 10 patients, treatment had to be stopped after one to three cycles due to progressive disease or hematological toxicity (n = 2). Non-hematological side effects were mild. Eight (13%) WHO grade 3 and no grade 4 events were observed in 60 evaluable treatment cycles. Hematologic toxicity was moderate (grade 3 and 4): anemia in five cycles (8%), leukopenia in seven (12%) and thrombocytopenia in eight (13%).
Conclusions:
Bendamustine as a single agent is effective against aggressive lymphoma, even in cases of refractory disease. Further studies are warranted to determine the significance of bendamustine in the treatment of aggressive lymphomas.
Key words: aggressive lymphoma, bendamustine, refractory disease, relapse
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. D. Cheson and M. J. Rummel Bendamustine: Rebirth of an Old Drug J. Clin. Oncol., March 20, 2009; 27(9): 1492 - 1501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Teichert, R. Sohr, F. Baumann, L. Hennig, K. Merkle, K. Caca, and R. Preiss SYNTHESIS AND CHARACTERIZATION OF SOME NEW PHASE II METABOLITES OF THE ALKYLATOR BENDAMUSTINE AND THEIR IDENTIFICATION IN HUMAN BILE, URINE, AND PLASMA FROM PATIENTS WITH CHOLANGIOCARCINOMA Drug Metab. Dispos., July 1, 2005; 33(7): 984 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Rummel, S. E. Al-Batran, S.-Z. Kim, M. Welslau, R. Hecker, D. Kofahl-Krause, K.-M. Josten, H. Durk, A. Rost, M. Neise, et al. Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma J. Clin. Oncol., May 20, 2005; 23(15): 3383 - 3389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Cheson What Is New in Lymphoma? CA Cancer J Clin, September 1, 2004; 54(5): 260 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pless, K. Belhadj, H. D. Menssen, W. Kern, B. Coiffier, J. Wolf, R. Herrmann, E. Thiel, D. Bootle, I. Sklenar, et al. Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma: Results from a Phase II Multicenter Study Clin. Cancer Res., February 15, 2004; 10(4): 1299 - 1305. [Abstract] [Full Text] [PDF]
|
|